Pascal Dô
Centre François Baclesse(FR)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, Medical Imaging Techniques and Applications, Cancer Genomics and Diagnostics
Most-Cited Works
- → Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial(2019)453 cited
- → Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial(2021)218 cited
- → Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)(2014)187 cited
- → Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients(2013)125 cited
- → BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers(2015)85 cited
- → 18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer(2016)52 cited
- → Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.(2017)51 cited
- → Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC(2018)51 cited
- → Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR -Mutated Advanced Non–Small Cell Lung Cancers(2017)43 cited
- → Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction(2016)41 cited